Japanese health authorities have approved a second regenerative medicine product derived from induced pluripotent stem (iPS) cells for coverage under the nation’s public health insurance system. This decision marks a significant milestone in the clinical application of stem cell technology within the country.
The approval allows patients to access this specific iPS-derived treatment with the financial support of the public insurance program. This development follows the precedent set by the first such product to receive similar coverage, further establishing a framework for integrating advanced regenerative therapies into Japan’s standard medical care.
In-depth summary · AI, neutral